Loading stock data…
$7.62-0.26 (-3.30%)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally.
Oculis Holding AG in the Healthcare sector is trading at $7.62 with a market capitalization of $469M. Wall Street consensus targets $36.36 (10 analysts), implying a +377.2% move over the next 12 months. The stock is currently near its 52-week low of $7.32, remaining 61.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$23.57M↓ | -$21.73M↓ | -$20.63M↓ | -$20.30M↑ | -$20.77M |
| Net Income | -$9.97M↑ | -$28.85M↓ | -$23.51M↓ | -$16.86M↑ | -$25.38M |
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dex...